Genome editing has advanced at a rapid pace with promising results for treating genetic conditions—but there is always room ...

Quantumzyme Corp. (OTC: QTZM), a biotechnology company leveraging computational enzyme engineering, is pleased to announce the upcoming publication of its patent for an innovative enzymatic method to ...

Genome editing has advanced at a rapid pace with promising results for treating genetic conditions -- but there is always room for improvement. A new paper showcases the power of scalable protein ...

SAN DIEGO, CA - April 16, 2025 (NEWMEDIAWIRE) - Quantumzyme Corp. (OTC: QTZM), a biotechnology company leveraging computational enzyme engineering, is providing insight into the company’s enzymatic ...

Researchers have developed a machine learning model that predicts Cas9 proteins that can be tailored with designer properties for therapeutic use.

By building a complete tool set—from enzyme engineering to pilot scale synthesis, we’re setting a new standard for what can be done with bio-based click chemistry.” Said Dr. John Billingsley ...

Genome editing has progressed rapidly, showing promising outcomes for the treatment of genetic disorders, yet there remains ...

Quantumzyme Corp. (OTC: QTZM), a biotechnology company leveraging computational enzyme engineering, is providing insight into the company's enzymatic design capabilities and current areas of ...